Compare Moderna, Inc. (MRNA) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Roblox Corp — how do they compare? Moderna, Inc. trades at $221.7 (market cap $78.65B), while Roblox Corp trades at $47.93 (market cap $32.52B). The key difference: Moderna, Inc. is far larger — about 2.4× Roblox Corp's market cap, and Moderna, Inc. is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Roblox Corp for 93 Days on average.
| MRNA | RBLX | |
|---|---|---|
Market Cap | $78.65B | $32.52B |
Volume | 37,373,437 | 14,552,045 |
Sector | Health | Technology |
52-Week High | $203.46 | $138.56 |
52-Week Low | $22.36 | $35.54 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | $74.80B | $31.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Roblox (RBLX) trades at $48.74, up 5.02% in the last session, with technical indicators showing bearish momentum despite recent price strength. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, while AI development tools show potential for long-term platform expansion.
The stock faces near-term headwinds from bearish technical signals and valuation concerns, but strong revenue growth and AI innovation provide long-term potential. Key risks include persistent profitability challenges and competitive pressures in the gaming sector, while analyst consensus suggests modest upside to the $50.85 price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
